New Therapeutics for Traumatic Brain Injury

<p>Part I. Interventional Therapies for TBI Previously or Currently in Phase 3 Clinical Trials<br>1. Why Did the Phase III Clinical Trials for Progesterone in TBI Fail? An Analysis of Three Potentially Critical Factors<br>2. Hypothermia for Traumatic Brain Injury: Current Evidence and Future Directions<br>3. The Future of TBI: Hyperbaric Oxygen as a Primary Therapeutic Approach</p> <p>Part II. Repurposing FDA Approved Drugs for TBI Treatment<br>4. Erythropoietin and Its Derivatives: Mechanisms of Neuroprotection and Challenges in Clinical Translation<br>5. Atorvastatin in the Treatment of Traumatic Brain Injury<br>6. The Application of Glibenclamide in Traumatic Brain Injury<br>7. Perispinal Etanercept for Traumatic Brain Injury</p> <p>Part III. Interventional Drugs for TBI in Phase 1–2 Clinical Trials<br>8. Nitric Oxide Synthase Inhibitors in Traumatic Brain Injury<br>9. Management of Paroxysmal Sympathetic Hyperactivity After Traumatic Brain Injury</p> <p>Part IV. Interventional Drugs for TBI in Preclinical Development<br>10. The Use of Estrogen for the Treatment of Traumatic Brain Injury<br>11. Voltage-Gated Calcium Channel Blockers for the Treatment of Traumatic Brain Injury<br>12. 5-Lipoxygenase-Activating Protein Inhibitors: Promising Drugs for Treating Acute and Chronic Neuroinflammation Following Brain Injury<br>13. Carbonyl Scavenging as an Antioxidant Neuroprotective Strategy for Acute Traumatic Brain Injury<br>14. TrkB Receptor Agonist 7,8-Dihydroxyflavone and Its Therapeutic Potential for Traumatic Brain Injury<br>15. Ceftriaxone Treatment of TBI</p> <p>Part V. Drugs for TBI Rehabilitation<br>16. Memantine: A Safe and Tolerable NMDA Antagonist with Potential Benefits in Traumatic Brain Injury<br>17. Interventional Drugs for TBI Rehabilitation of Cognitive Impairment: The Cholinesterase Inhibitor Rivastigmine<br>18. Docosahexaenoic Acid and Omega 3 Fatty Acids<br>19. Treatment of Mood Disorders Following Traumatic Brain Injury</p>